Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C1917/17 genotype.

British journal of clinical pharmacology - 1 Oct 2015

Bennis Youssef, Bodeau Sandra, Bouquié Régis, Deslandes Guillaume, Verstuyft Céline, Gruson Bérangère, Andréjak Michel, Lemaire-Hurtel Anne-Sophie, Chouaki Taieb

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antifungal Agents
Share to Aspergillosis
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to Homozygote

Share to Oxidation-Reduction

Share to Treatment Failure

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 26138512
DOI: 10.1111/bcp.12713
PMCID: PMC4594719

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype.PMID 26138512Read ↗

Dual toxicity of voriconazole in a CYP2C19 poor metabolizer: A case analysis of Life-threatening neutropenia and hepatocellular injurySemantic proximity Read ↗

Unravelling Voriconazole's Hepatic Metabolism: A Narrative Review on Factors Impacting Voriconazole-N-Oxide Exposure.Semantic proximity Read ↗

Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.Semantic proximity Read ↗

The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.Semantic proximity Read ↗

Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies.Semantic proximity Read ↗

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Semantic proximity Read ↗

Association ofCYP2C19*17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell CarcinomaSemantic proximity Read ↗

Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.Semantic proximity Read ↗

Why are the Therapeutic Drug Monitoring Results of Voriconazole Inconsistent with CYP2C19 Genetic Testing?Semantic proximity Read ↗

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.Semantic proximity Read ↗

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers.Semantic proximity Read ↗

Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.